Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients
Gregory S Sawicki, Will Chou, Karina Raimundo, Ben Trzaskoma, Michael W Konstan, Gregory S Sawicki, Will Chou, Karina Raimundo, Ben Trzaskoma, Michael W Konstan
Abstract
Background: Dornase alfa administered via jet nebulizer is indicated as a chronic respiratory medication for cystic fibrosis (CF) patients. Efficacy and safety of dornase alfa via an electronic nebulizer with vibrating membrane technology have not been formally assessed in randomized clinical trials.
Methods: 87 CF patients (≥6 years) were randomized in a crossover study to receive dornase alfa 2.5 mg/d in 2-week periods with the Pari eRapid and Pari LC Plus jet nebulizers. The primary end point was comparison of forced expiratory volume in the first second. Safety, quality of life, and treatment satisfaction/preference were also compared between devices.
Results: Lung function was equivalent between nebulizers. Most domain scores from the Cystic Fibrosis Questionnaire-Revised and Treatment Satisfaction Questionnaire for Medication instruments were similar but patients strongly preferred the eRapid. Mean patient-reported administration times were shorter with the eRapid vs the LC Plus (2.7 vs 10.2 min). Adverse events were similar between devices.
Conclusions: Administration of dornase alfa via the eRapid nebulizer resulted in comparable efficacy and safety, shorter nebulization times, and higher patient preference.
Trial registration: ClinicalTrials.gov NCT01712334.
Keywords: Cystic fibrosis; Dornase alfa; Nebulizers.
Copyright © 2015 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
Source: PubMed